Latest Revenue Forecast News

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

FlexiRoam has broadened its partnership with a top-10 global airline to include critical aircraft connectivity and secured a two-year deal with Malaysian payment innovator Paydibs, underscoring its growing enterprise footprint.

Metro Performance Glass reports solid operational gains and a stronger balance sheet amid ongoing construction market challenges, though revenue falls short of earlier forecasts.

Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

Jcurve Solutions has reported a robust first half of FY26, posting a 32% increase in revenue and a remarkable 478% jump in EBITDA, while upgrading its full-year revenue guidance amid ongoing customer churn challenges.

Frontier Energy has secured 88.06 MW of peak capacity credits for its Waroona Project, guaranteeing around $32 million annually for five years, while raising $11.5 million to advance debt financing and project development.

Weebit Nano has landed its largest customer yet with Texas Instruments licensing its ReRAM technology, while achieving key technical milestones and doubling its revenue guidance for FY26.

Ava Risk Group reports a softer first half with delayed orders impacting revenue, but anticipates a robust recovery in the second half backed by new contracts and a strategic investment.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Pureprofile Limited has upgraded its FY26 revenue guidance after a record first half, driven by strong international growth and a booming platform business. The Rest of World segment now outpaces ANZ, signalling a major shift in the company’s geographic footprint.